Live Breaking News & Updates on Longitudinal|Page 2

Stay updated with breaking news from Longitudinal. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

MyJournals.org - Science - 'Clinical phenotypes and prognostic factors in persons with hip osteoarthritis undergoing total hip arthroplasty: protocol for a longitudinal prospective cohort study (HIPPROCLIPS)' (BMC Musculoskeletal Disorders)

MyJournals.org - Science - Clinical phenotypes and prognostic factors in persons with hip osteoarthritis undergoing total hip arthroplasty: protocol for a longitudinal prospective cohort study (HIPPROCLIPS) (BMC Musculoskeletal Disorders) ....

Ipproclips ,

"COVID-19: Impact on children living in out-of-home care and their care" by Michelle L. Townsend, Michael Tarren-Sweeney et al.

Children enter out-of-home care (OOHC) having experienced significant childhood adversities and trauma. Little is known about the short-term impacts of the COVID-19 pandemic on this vulnerable group. To gain some insights, we analysed the early impacts on the well-being and experiences of children in OOHC and their carers using the Pathways of Care Longitudinal Study data prior to and post the first lockdown restrictions. A total of 862 children, young people and their carers were interviewed either pre-COVID-19 restrictions (n = 567) (April 2019–March 2020) or post-COVID-19 restrictions (n = 295) (June–December 2020). While the two groups showed no significant differences in socio-emotional well-being, both the pre- and the post-COVID-19 restriction groups of children in OOHC had slight reductions in socio-emotional well-being. The interviews with the post-COVID-19 group showed that the pandemic restrictions affected children's well-being and behaviour, education, social and ....

Care Longitudinal Study , Covid 19 Pandemic , Out Of Home Care ,

Certa Therapeutics' investigational drug FT011 delivers breakthrough results as a potential novel treatment for serious inflammatory and fibrotic diseases

Research presented today by University of Michigan Medical School highlights FT011's ground-breaking treatment potential from human expression profiles in chronic kidney disease study supported by animal model data The research demonstrated that treatment with FT011 results in a remarkable reversal in the activation of genetic markers associated with fibrosis Fibrosis is responsible for 45 percent of all deaths globally - FT011 is a novel drug with potential to treat chronic fibrosis in multiple organs such as the kidneys, skin, lungs, heart, and eyes Certa Therapeutics is a clinical stage biotechnology company based in Melbourne, Australia, developing innovative therapies for the treatment of fibrotic diseases ANN ARBOR, Mich., Nov. 4, 2022 /PRNewswire/ New research presented today by the University of Michigan reveals ground-breaking results for Certa Therapeutics' FT011, a novel potential treatment of serious inflammatory and fibrotic diseases. The results in a chronic kid ....

United States , Matthias Kretzler , Darren Kelly , Rare Disease Clinical Research Network , National Center , Nephrotic Syndrome Study Network , Translational Sciences , University Of Michigan , Nephcure Kidney International , University Of Michigan Medical School Professor , Halpin Foundation , American Society Of Nephrology , University Of Michigan Medical School , Alport Syndrome Foundation , Michigan Medical School , Certa Therapeutic , Kidney Week , American Society , Professor Darren Kelly , Focal Segmental Glomerulosclerosis , Membranous Nephropathy , Michigan Medical School Professor , Lacerta Therapeutics , Minimal Changes Disease , Nephrotic Syndrome , Advancing Translational Sciences ,